Cargando…
Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy
Histone deacetylase (HDAC) enzymes play a critical role in the epigenetic regulation of cellular functions and signaling pathways in many cancers. HDAC inhibitors (HDACi) have been validated for single use or in combination with other drugs in oncologic therapeutics. An even more novel combination t...
Autores principales: | Nakashima, Hiroshi, Nguyen, Tran, Chiocca, Ennio Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918398/ https://www.ncbi.nlm.nih.gov/pubmed/27512681 http://dx.doi.org/10.2147/OV.S66081 |
Ejemplares similares
-
Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
por: Marchini, Antonio, et al.
Publicado: (2016) -
Deep learning of magnetic resonance fingerprints for the quantitative
imaging of apoptosis following oncolytic virotherapy
por: Perlman, Or, et al.
Publicado: (2022) -
Development of oncolytic virotherapy: from genetic modification to combination therapy
por: Lan, Qiaoshuai, et al.
Publicado: (2020) -
Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy
por: Mamola, Joseph A., et al.
Publicado: (2023) -
Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy
por: Binz, Eike, et al.
Publicado: (2015)